Status:
COMPLETED
The Impact of PCCM on Healthcare Among Asthma or Chronic Obstructive Pulmonary Disease (COPD) or Asthma-COPD Overlap Patients
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
COPD
Eligibility:
All Genders
18+ years
Brief Summary
A Multi-centre, retrospective study describing the impact of PCCM standardized implementation on healthcare management among Asthma or COPD or Asthma-COPD overlap patients in Tianjin city of China, us...
Detailed Description
This is a multi-center retrospective study to describe the impact of PCCM on healthcare management of Asthma or COPD or ACO patients in Tianjin healthcare big data platform database in China from Jan ...
Eligibility Criteria
Inclusion
- Of note, the following criteria will be applied separately to the pre-PCCM period and post-PCCM period.
- Asthma:
- Patients were age 18 years and older.
- Patients had Asthma diagnosis record according to the International Classification of Disease 10th edition (ICD-10) codes J45,J45.x, J46, J46.x.
- COPD:
- Patients were age 18 years and older.
- Patients had COPD diagnosis record according to the International Classification of Disease 10th edition (ICD-10) codesJ44 and J44.x (including the other clinical diagnostic records for COPD diagnosis codes: the other clinical diagnostic records will be defined as chronic bronchitis or emphysema or chronic wheeze bronchitis+ at least one of the following prescribed medicine which will be defined as ICS, LABA, LAMA, ICS/LABA, LABA/LAMA, ICS/LABA/LAMA, theophylline (sustained) , systemic glucocorticoids (IV/Oral), SAMA, SABA, SABA/SAMA).
- ACO:
- Patients were age 18 years and older.
- Patients had both COPD and Asthma diagnosis in a single record or within one year according to the International Classification of Disease 10th edition (ICD-10) codes J44, J44.x, J45,J45.x, J46 and J46.x.
Exclusion
- Asthma
- Patients with any history of diagnosis of COPD.
- Patients had new diagnosis of COPD during Asthma follow up period.
- COPD
- Patients with any history of diagnosis of Asthma or bronchiectasis, interstitial lung disease(i.e. pulmonary fibrosis).
- Patients had new diagnosis of Asthma during COPD follow up period.
- ACO • Patients with any history of diagnosis of bronchiectasis, interstitial lung disease (i.e. pulmonary fibrosis).
Key Trial Info
Start Date :
December 8 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 12 2023
Estimated Enrollment :
288538 Patients enrolled
Trial Details
Trial ID
NCT04905420
Start Date
December 8 2021
End Date
June 12 2023
Last Update
July 31 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianjin Chest Hospital
Tianjin, China